IFNA1 and hepatocellular carcinoma: In Japan, Kobayashi et al. reported a cumulative HCC incidence (3-/5-year) of 1.30/3.03% for IFN-free and 1.02/2.19% for IFN-based therapy during the follow-up period (median, 4.0 years and 7.3 years, respectively), with a log-rank test indicating no significant differences in either group27.